Tumor-associated macrophages: Implications in cancer immunotherapy

Immunotherapy

Volumn 9, Issue 3, 2017, Pages 289-302

  Petty, Amy J ^a   Yang, Yiping ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

immunotherapy; tumor microenvironment; tumor associated macrophages (TAM)

Indexed keywords

AMG 820; BLZ 945; CARLUMAB; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; DACARBAZINE; DNA VACCINE; DOXORUBICIN; EMACTUZUMAB; ERIBULIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMC CS4; IMIQUIMOD; IRINOTECAN; LEGUMAIN; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; OXALIPLATIN; PACLITAXEL; PDR 001; PF 04136309; PLX 3397; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; EPITHELIAL MESENCHYMAL TRANSITION; GIANT CELL TUMOR; GIANT CELL TUMOR OF TENDON SHEATH; GLIOBLASTOMA; HUMAN; IMMUNOSURVEILLANCE; LEIOMYOSARCOMA; LIPOSARCOMA; MELANOMA; METASTASIS; METASTATIC BREAST CANCER; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PLEURA MESOTHELIOMA; REVIEW; SKIN METASTASIS; SOFT TISSUE SARCOMA; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; ANIMAL; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROCEDURES;

ANIMALS; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MACROPHAGES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85014029818     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0135     Document Type: Review

References (98)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 144(5), 646-674 (2011).
2. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19(11), 1423-1437 (2013).
3. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11(10), 889-896 (2010).
4. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 141(1), 39-51 (2010).
5. Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 14(6), 392-404 (2014).
6. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122(3), 787-795 (2012).
7. Xue J, Schmidt SV, Sander J et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40(2), 274-288 (2014).
8. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 229(2), 176-185 (2013).
9. Biswas SK, Gangi L, Paul S et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/ STAT1 activation). Blood 107(5), 2112-2122 (2006).
10. Hashimoto D, Chow A, Noizat C et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38(4), 792-804 (2013).
11. Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell. Mol. Immunol. 12(1), 1-4 (2015).
12. Williams CB, Yeh ES, Soloff AC. Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer 2, 15025 (2016).
13. Franklin RA, Li MO. Ontogeny of tumor-associated macrophages and its implication in cancer regulation. Trends. Cancer. 2(1), 20-34 (2016).
14. Movahedi K, Laoui D, Gysemans C et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70(14), 5728-5739 (2010).
15. Franklin RA, Liao W, Sarkar A et al. The cellular and molecular origin of tumor-associated macrophages. Science 344(6186), 921-925 (2014).
16. Shand FHW, Ueha S, Otsuji M et al. Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. PNAS 111(21), 7771-7776 (2014).
17. Linde N, Lederle W, Depner S, Van Rooijen N, Gutschalk CM, Mueller MM. Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J. Pathol. 227(1), 17-28 (2012).
18. Qian B-Z, Li J, Zhang H et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 475(7355), 222-225 (2011).
19. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1), 49-61 (2014).
20. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization; enabling diversity with identity. Nat. Rev. Immunol. 11(11), 750-761 (2011).
21. Colegio OR, Chu N-Q, Szabo AL et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513(7519), 559-563 (2014).
22. Heusinkveld M, Van Der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 9, 216 (2011).
23. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141(1), 52-67 (2010).
24. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8(8), 618-631 (2008).
25. Valkovic T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonjic N. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch. 440(6), 583-588 (2002).
26. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 67(11), 5064-5066 (2007).
27. Forget MA, Voorhees JL, Cole SL et al. Macrophage colony-stimulating factor augments tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. PLoS ONE. 9(6), e98623 (2014).
28. Yeo EJ, Cassetta L, Qian BZ et al. Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. Cancer Res. 74(11), 2962-2973 (2014).
29. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2), 263-266 (2006).
30. Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer 12, 35 (2012).
31. Wyckoff JB, Wang Y, Lin EY et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 67(6), 2649-2656 (2007).
32. Sangaletti S, Di Carlo E, Gariboldi S et al. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res. 68(21), 9050-9059 (2008).
33. Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 6(3), 1670-1690 (2014).
34. Chen J, Yao Y, Gong C et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 19(4), 541-555 (2011).
35. Qian B, Deng Y, Im JH et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 4(8), e6562 (2009).
36. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 14(3), 275-291 (2014).
37. Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: Attacking cancer's inflammatory roots. Clin. Cancer Res. 17(19), 6125-6129 (2011).
38. Schwitalla S, Fingerle AA, Cammareri P et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152(1-2), 25-38 (2013).
39. Wan S, Zhao E, Kryczek I et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 147(6), 1393-1404 (2014).
40. Yang Z, Xie H, He D, Li L. Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling. Oncotarget 7(28), 44478-44491 (2016).
41. Lu H, Clauser KR, Tam WL et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat. Cell Biol. 16(11), 1105-1117 (2014).
42. Yang J, Liao D, Chen C et al. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 31(2), 248-258 (2013).
43. Jinushi M, Chiba S, Yoshiyama H et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. PNAS 108(30), 12425-12430 (2011).
44. Mitchem JB, Brennan DJ, Knolhoff BL et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73(3), 1128-1141 (2013).
45. Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 212, 435-445 (2015).
46. Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am. J. Transl. Res. 4(4), 376-389 (2012).
47. Koebel CM, Vermi W, Swann JB et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450(7171), 903-907 (2007).
48. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14(10), 1014-1022 (2013).
49. Mortarini R, Piris A, Maurichi A et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 63(10), 2535-2545 (2003).
50. Munn DH, Sharma MD, Baban B et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity 22(5), 633-642 (2005).
51. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109(4), 1568-1573 (2007).
52. Rodriguez PC, Zea AH, Desalvo J et al. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 171(3), 1232-1239 (2003).
53. Mazzoni A, Bronte V, Visintin A et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168(2), 689-695 (2002).
54. Kalinski P. Regulation of immune responses by prostaglandin E2. J. Immunol. 188(1), 21-28 (2012).
55. Oh SA, Li MO. TGF-beta: guardian of T cell function. J. Immunol. 191(8), 3973-3979 (2013).
56. Ruffell B, Chang-Strachan D, Chan V et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26(5), 623-637 (2014).
57. Kuang DM, Zhao Q, Peng C et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206(6), 1327-1337 (2009).
58. Ojalvo LS, King W, Cox D, Pollard JW. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am. J. Pathol. 174(3), 1048-1064 (2009).
59. Noman MZ, Desantis G, Janji B et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T-cell activation. J. Exp. Med. 211(5), 781-790 (2014).
60. Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy. Blood 121(5), 734-744 (2013).
61. Sica A, Saccani A, Bottazzi B et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 164(2), 762-767 (2000).
62. Krneta T, Gillgrass A, Poznanski S et al. M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner. J. Leukoc. Biol. doi:10. 1189/jlb. 3A1215-552R (2016) (Epub ahead of print).
63. Liu D, Song L, Wei J et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J. Clin. Invest. 122(6), 2221-2233 (2012).
64. Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front. Immunol. 4, 190 (2013).
65. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004).
66. Liu J, Zhang N, Li Q et al. Tumor-associated macrophages recruit ccr6+ regulatory t cells and promote the development of colorectal cancer via enhancing ccl20 production in mice. PLoS ONE 6(4), e19495 (2011).
67. Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nature Immunol. 8(10), 1086-1094 (2007).
68. Savage ND, De Boer T, Walburg KV et al. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J. Immunol. 181(3), 2220-2226 (2008).
69. Daurkin I, Eruslanov E, Stoffs T et al. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res. 71(20), 6400-6409 (2011).
70. Pucci F, Venneri MA, Biziato D et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood 'resident' monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood. 114(4), 901-914 (2009).
71. Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125(9), 3365-3376 (2015).
72. Corzo CA, Condamine T, Lu L et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207(11), 2439-2453 (2010).
73. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 496(7446), 445-455 (2013).
74. Lesokhin AM, Hohl TM, Kitano S et al. Monocytic CCR2+ myeloid derived suppressor cells promote immune escape by limiting activated CD8 T cell infiltration into the tumor microenvironment. Cancer Res. 72(4), 876-886 (2012).
75. Chang AL, Miska J, Wainwright DA et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res. 76(19), 5671-5682 (2016).
76. Sanford DE, Belt BA, Panni RZ et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: A role for targeting the CCL2/CCR2 axis. Clin. Cancer Res. 19(13), 3404-3415 (2013).
77. Lu X, Kang Y. Chemokine (C-C Motif) ligand 2 engages CCR2(+) stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J. Biol. Chem. 284(42), 29087-29096 (2009).
78. Nywening TM, Wang-Gillam A, Sanford DE et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resec and locally advanced pancreatic cancer: A single-centre, open-label, dose-finding, non-randomised, Phase 1b trial. Lancet Oncol. 17(5), 651-662 (2016).
79. Brana I, Calles A, Lorusso PM et al. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: An open-label, multicenter Phase 1b study. Targeted Oncol. 10(1), 111-123 (2015).
80. Sandhu SK, Papadopoulos K, Fong PC et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother. Pharmacol. 71(4), 1041-1050 (2013).
81. DeNardo DG, Brennan DJ, Rexhepaj E et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1(1), 54-67 (2011).
82. Pyonteck SM, Akkari L, Schuhmacher AJ et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19(10), 1264-1272 (2013).
83. Strachan DC, Ruffell B, Oei Y et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology 2(12), e26968 (2013).
84. Zhang C, Ibrahim PN, Zhang J et al. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. PNAS 110(14), 5689-5694 (2013).
85. Mok S, Koya RC, Tsui C et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 74(1), 153-161 (2014).
86. Stafford JH, Hirai T, Deng L et al. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro-oncology 18(6), 797-806 (2016).
87. Tap WD, Wainberg ZA, Anthony SP et al. Structure-guided blockade of csf1r kinase in tenosynovial giant-cell tumor. N. Engl. J. Med. 373(5), 428-437 (2015).
88. Ries CH, Cannarile MA, Hoves S et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25(6), 846-859 (2014).
89. Germano G, Frapolli R, Simone M et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 70(6), 2235-2244 (2010).
90. Germano G, Frapolli R, Belgiovine C et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23(2), 249-262 (2013).
91. Demetri GD, Von Mehren M, Jones RL et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a Phase III randomized multicenter clinical trial. J. Clin. Oncol. 34(8), 786-793 (2016).
92. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J. Clin. Oncol. 28(19), 3107-3114 (2010).
93. Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front. Immunol. 5, 614 (2014).
94. Dewan MZ, Vanpouille-Box C, Kawashima N et al. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin. Cancer Res. 18(24), 6668-6678 (2012).
95. Singh M, Khong H, Dai Z et al. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J. Immunol. 193(9), 4722-4731 (2014).
96. Niu M, Valdes S, Naguib YW, Hursting SD, Cui Z. Tumor-associated macrophage-mediated targeted therapy of triple-negative breast cancer. Mol. Pharm. 13(6), 1833-1842 (2016).
97. Luo Y, Zhou H, Krueger J et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116(8), 2132-2141 (2006).
98. Shen K-Y, Song Y-C, Chen IH, Chong P, Liu S-J. Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide. Hum. Vaccin. Immunother. 10(11), 3241-3250 (2014).